LMU University Hospital, Germany
Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, LMU University Hospital, Munich, Germany. She obtained her specialist degree (OB&GYN) at the Technical University of Munich (TUM) and her medical degree from the Ludwig-Maximilians University of Munich (LMU).
Professor Harbeck is a member of the expert panel issuing the German AGO recommendations for breast cancer therapy (www.ago-online.de). She is co-director of the West German Study Group (www.wsg-online.com). From 2009-2015, she served on the executive board of the EORTC. In 2020, she was appointed subject editor for the ESMO Breast Cancer Guidelines. Professor Harbeck is a principal investigator or steering committee member of numerous breast cancer trials, particularly with novel targeted compounds and individualized treatment strategies. She has a strong interest in eHealth and is a co-developer of CANKADO, an international digital patient diary (www.cankado.com).
Professor Harbeck is one of the most frequently cited clinical researchers worldwide (highly cited researchers 2021). She has authored about 550 papers in peer-reviewed journals (h-index 87) and is coordinating editor-in-chief of Breast Care (Karger Publishers). She is a panel member of several international breast cancer consensus conferences.
Professor Harbeck is recipient of the 2020 ESMO Lifetime Achievement Award. She also received several additional recognitions of her clinical and translational research such as the 2021 UPO Award for Women in Academy and Research, the 2015 Bavarian Cancer Patient Award, the 2012 Claudia von Schilling Award, the 2008 EBCC Award, the 2002 AGO Schmidt-Matthiesen Award, a 2001 AACR Award, and the 2001 ASCO Fellowship Merit Award for the highest ranking abstract.
Honoraria – AstraZeneca, Exact Sciences, Lilly, Novartis, Pfizer
Contract of employment – Co-Director West German Study Group
Professor of Breast Cancer Medicine, Consultant Medical Oncologist and Head of The Breast Unit at the Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London
Stephen Johnston is Professor of Breast Cancer Medicine, Consultant Medical Oncologist and Head of The Breast Unit at the Royal Marsden NHS Foundation Trust & Institute of Cancer Research, London. He was appointed Head of Medical Oncology at The Royal Marsden in 2019, having previously been the first Director of the UK’s National Institute for Health Research (NIHR) Biomedical Research Centre for Cancer at The Royal Marsden from 2006-12.
He graduated in 1983 from Trinity College at The University of Cambridge, and in 1986 from The Medical School at The University of Newcastle upon Tyne. He trained in General Medicine at St Bartholomew’s Hospital and Hammersmith Hospital in London, and subsequently in Medical Oncology at the Royal Marsden Hospital. He gained his PhD from the Institute of Cancer Research at the University of London, and took up his current position as Consultant Medical Oncologist on the Breast Unit at the Royal Marsden Hospital in 1997.
He has a specialist interest in the treatment of metastatic breast cancer, and his major research interests lie in understanding mechanisms of endocrine resistance in breast cancer. He is actively involved in facilitating the interface between basic and applied research, and has been Chief Investigator of several phase II / III trials of novel endocrine based therapeutic approaches in both advanced and early stage disease, including one of the large global adjuvant CDK 4/6 inhibitor studies in early breast cancer. He has published over 260 breast cancer related articles in peer-reviewed journals, and is a regular invited lecturer at national & international meetings.
He is a member of various scientific committees and international advisory boards, has served as Faculty Member at the American Society for Clinical Oncology and is currently on the Scientific Committee in the European Society for Medical Oncology.
Disclosures:Honoraria – Eli Lilly, AstraZeneca, Puma Biotech, Pfizer, Novartis, Sanofi Genzyme, Eisai, Roche/Genentech
Patient Advocate, Neubiberg, Germany
Medical Journalist, consultant, Founder and President of the German Breast Cancer Association – Brustkrebs Deutschland e.V.
Following completion of Renate’s university-entrance diploma, she worked as a freelance journalist, specializing in psychology and medicine in 1987. In December 2000, Mrs. Haidinger was diagnosed with breast cancer. After several surgeries and chemotherapy, she founded a local advocacy group, brustkrebs-muenchen e.V., in December 2001, and in 2003 co-founded the nationwide organization Brustkrebs Deutschland e.V. (German Breast Cancer Association) with a group of doctors, breast cancer patients and others. From 2002 Mrs. Haidinger began offering a weekly consultation session at the Munich University Clinic, Munich-Großhadern.
Since 2005 she has professionally attended all relevant breast cancer conferences, recording video interviews with German experts and live streams from ASCO and SABCS. She writes content for a number of breast cancer websites and brochures, moderates podium discussions, and gives multiple annual presentations on HTA issues and market access, among other topics concerning patients
She has been a member of numerous advocacy, advisory board, and working groups, and holds memberships with many breast cancer societies. She also works with the European Medicines Agency and the European Commission, and is an appointed member of the innovative medicines initiative pool of patient experts. At the virtual ABC6 conference in 2021 she was member of the patient advocacy committee, faculty and panel member as well as co-chair of the consensus meeting.
In recent years she has worked for the ABC Global Alliance and was elected “Director of the General Assembly” in 2019. She has co-authored many breast cancer publications listed in PubMed. In 2012 Mrs. Haidinger received the Federal Cross of Merit from the German President, Joachim Gauck.
Sign up for new content alerts
Enter your email address below and we'll contact you as soon as new content is launched!